Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 4;12(1):82.
doi: 10.3390/biology12010082.

Nanoparticle Based Cardiac Specific Drug Delivery

Dong Li  1   2 , Yura Son  1 , Michelle Jang  1   3 , Shu Wang  4 , Wuqiang Zhu  1
Affiliations
Review

Nanoparticle Based Cardiac Specific Drug Delivery

Dong Li et al. Biology (Basel). .

Abstract

Heart failure secondary to myocardial injuries is a leading cause of death worldwide. Recently, a growing number of novel therapies have emerged for injured myocardium repairment. However, delivering therapeutic agents specifically to the injured heart remains a significant challenge. Nanoparticles are the most commonly used vehicles for targeted drug delivery. Various nanoparticles have been synthesized to deliver drugs and other therapeutic molecules to the injured heart via passive or active targeting approaches, and their targeting specificity and therapeutic efficacies have been investigated. Here, we summarized nanoparticle-based, cardiac-specific drug delivery systems, their potency for treating heart diseases, and the mechanisms underlying these cardiac-targeting strategies. We also discussed the clinical studies that have employed nanoparticle-based cardiac-specific drug delivery.

Keywords: cardiac; ischemia; myocardial; nanomaterial; nanoparticle; targeted delivery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Illustration of nanoparticle-based drug delivery for the treatment of myocardial injuries. Approaches to process nanoparticles for cardiac-specific delivery of therapeutic agents (upper panel). Intravenous administration of cardiac-targeting nanoparticles for myocardial regeneration and repair (lower panel). Note: we used nanosphere in this illustration to represent polymeric NPs.
Figure 2
Figure 2
Pathological left ventricular remodeling post-myocardial infarction. (A) The recruitment of monocytes to infarct myocardium and the phenotype switching of macrophages. (B) Platelet activation, adhesion, and aggregation in the damaged site of the vascular endothelium. (C) Opening of the mitochondrial permeability transition pore (MPTP) and increased mitochondrial outer membrane permeability (MOMP) lead to mitochondrial dysfunction and cell death.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Li J., Hu S., Zhu D., Huang K., Mei X., López de Juan Abad B., Cheng K. All Roads Lead to Rome (the Heart): Cell Retention and Outcomes From Various Delivery Routes of Cell Therapy Products to the Heart. J. Am. Heart Assoc. 2021;10:e020402. doi: 10.1161/JAHA.120.020402. - DOI - PMC - PubMed
    1. Sahoo S., Kariya T., Ishikawa K. Targeted delivery of therapeutic agents to the heart. Nat. Rev. Cardiol. 2021;18:389–399. doi: 10.1038/s41569-020-00499-9. - DOI - PMC - PubMed
    1. Razavi E., Ramezani A., Kazemi A., Attar A. Effect of Treatment with Colchicine after Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials. Cardiovasc. Ther. 2022;2022:8317011. doi: 10.1155/2022/8317011. - DOI - PMC - PubMed
    1. Wang D., Liu B., Xiong T., Yu W., Yang H., Wang J., Jing X., She Q. Transcription factor Foxp1 stimulates angiogenesis in adult rats after myocardial infarction. Cell Death Discov. 2022;8:381. doi: 10.1038/s41420-022-01180-5. - DOI - PMC - PubMed
    1. Monahan D.S., Almas T., Wyile R., Cheema F.H., Duffy G.P., Hameed A. Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities. Drug Deliv. Transl. Res. 2021;11:1924–1942. doi: 10.1007/s13346-020-00885-3. - DOI - PubMed

Grants and funding

The work was supported by American Heart Association Grant #19AIREA34480011 (to S.W.), and Mayo Clinic Startup funds (to W.Z.).

LinkOut - more resources